MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q1 2024 · 38 positions · Total reported value $621.98M · Top-10 concentration 55.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, MPM BioImpact LLC disclosed 38 equity positions with a combined reported value of $621.98M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.5% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were CGEM ($130.33M), GERN ($34.57M), IOVA ($32.60M). By sector, the heaviest allocations are Health Care 78.5%, Materials 1.3%. Versus the prior quarter, allocation shifted toward Health Care (+8.0pp) and away from Other (-8.4pp).

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q1 2024 were ZNTL ($23.90M), STRO ($23.15M), NTRA ($15.77M).

Of the 11 positions fully exited versus the prior quarter, the largest were KRTX ($16.86M), CBAY ($14.44M), GPCR ($9.40M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • ZNTL ZENTALIS PHARMACEUTICALS INC · $23.90M
  • STRO SUTRO BIOPHARMA INC · $23.15M
  • NTRA NATERA INC · $15.77M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · $11.47M
  • ETNB 89BIO INC · $11.26M
  • FULC FULCRUM THERAPEUTICS INC · $10.73M
  • KALV KALVISTA PHARMACEUTICALS INC · $9.02M
  • AKRO AKERO THERAPEUTICS INC · $8.41M

Fully Exited (vs previous quarter)

  • KRTX KARUNA THERAPEUTICS INC · prev qtr: $16.86M
  • CBAY CYMABAY THERAPEUTICS INC · prev qtr: $14.44M
  • GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $9.40M
  • HARP HARPOON THERAPEUTICS INC · prev qtr: $3.63M
  • INZY INOZYME PHARMA INC · prev qtr: $1.38M
  • PHAT Phathom Pharmaceuticals, Inc. · prev qtr: $639.10K

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.5%
Materials 1.3%
Other 20.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 7.65M $130.33M 20.95%
20.95%
Hold
2 10.48M $34.57M 5.56%
5.56%
Reduce
3 2.20M $32.60M 5.24%
5.24%
Reduce
4 1.52M $23.90M 3.84%
3.84%
New
5 1.75M $23.81M 3.83%
3.83%
Hold
6 4.10M $23.15M 3.72%
3.72%
New
7 480.59K $22.50M 3.62%
3.62%
Hold
8 1.95M $22.12M 3.56%
3.56%
Add
9 61.40K $16.40M 2.64%
2.64%
Add
10 172.41K $15.77M 2.54%
2.54%
New
11 2.39M $15.47M 2.49%
2.49%
Hold
12 296.05K $14.87M 2.39%
2.39%
Add
13 871.15K $14.71M 2.37%
2.37%
Add
14 530.79K $14.40M 2.31%
2.31%
Add
15 1.27M $14.14M 2.27%
2.27%
Hold
16 150.00K $12.30M 1.98%
1.98%
Reduce
17 432.60K $11.90M 1.91%
1.91%
Add
18 549.08K $11.57M 1.86%
1.86%
Hold
19 245.59K $11.47M 1.84%
1.84%
New
20 325.33K $11.45M 1.84%
1.84%
Hold
21 967.74K $11.26M 1.81%
1.81%
New
22 614.01K $10.75M 1.73%
1.73%
Add
23 1.14M $10.73M 1.73%
1.73%
New
24 4.17M $9.21M 1.48%
1.48%
Add
25 114.13K $9.11M 1.46%
1.46%
Add
26 760.72K $9.02M 1.45%
1.45%
New
27 273.22K $8.81M 1.42%
1.42%
Hold
28 638.16K $8.47M 1.36%
1.36%
Hold
29 718.97K $8.47M 1.36%
1.36%
Hold
30 332.92K $8.41M 1.35%
1.35%
New
31 5.10M $8.05M 1.29%
1.29%
Hold
32 441.26K $8.05M 1.29%
1.29%
New
33 1.64M $7.72M 1.24%
1.24%
Hold
34 832.02K $6.91M 1.11%
1.11%
Hold
35 110.78K $6.90M 1.11%
1.11%
Add
36 1.34M $4.63M 0.74%
0.74%
New
37 395.24K $4.15M 0.67%
0.67%
New
38 1.97M $3.90M 0.63%
0.63%
New

FAQ

What did MPM BioImpact LLC buy in 2024-Q1?

In its 2024-Q1 13F filing, MPM BioImpact LLC reported 38 equity positions worth $621.98M in aggregate; its largest disclosed positions were CGEM ($130.33M), GERN ($34.57M), IOVA ($32.60M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $621.98M of long equity holdings across 38 positions as of 2024-Q1. Top-10 holdings account for 55.5% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →